SRB5 / SunRock Biopharma - LARVOL DELTA

SRB5 DEMONSTRATES ROBUST EX VIVO ACTIVITY ACROSS BIONAÏVE AND BIOEXPOSED ULCERATIVE COLITIS PATIENTS (UEGW 2026) - No abstract available

Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

SRB5 (anti-CCR9) shows superior ex vivo activity versus a clinically advanced anti‑CCR9 benchmark in IBD (ECCO-IBD 2026) - "Conclusion SRB5 induces robust, selective depletion of pathogenic CCR9⁺ T cells and a marked reduction of key pro-inflammatory cytokines, defining a potent anti-inflammatory signature in human IBD tissue. In preclinical patient-derived head-to-head assays, SRB5 outperformed clinically advanced EBA-CCR9 through a distinct non–ligand-blocking epitope, supporting a best-in-class potential for IBD."

Metastases • Preclinical • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis • CD4

SunRock Biopharma…announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications (Businesswire) - "Through this partnership, SunRock will benefit from Chime Biologics’ global-standard GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones."

Licensing / partnership • Inflammatory Bowel Disease